Abiopharma

🔍 Sherbin Joshua A (Executive)

Company: Dauch Corp (DCH)

Report Date: 2026-05-04

Detailed Transactions and Holdings:

• Acquired 45,455 shares of Common Stock (Direct)
  Date: 2026-05-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 45,455.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Acquired 100,747 shares of Common Stock (Direct)
  Date: 2026-05-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 146,202.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: These shares represent a grant of performance-based restricted stock units ("PSUs") at target level performance. The actual number of PSUs that will be achieved is based on the highest average price of the Company's common stock achieved over any 20-day trading period during the measurement period ending March 31, 2029 ("Performance Period"). The number of PSUs earned by the reporting person will not exceed 300% of target. The PSUs will generally vest 50% at the end of the Performance Period and 50% on the one-year anniversary thereof.
• F2: These shares represent a grant of restricted stock units ("RSUs") that will settle in common stock upon vesting on the third anniversary of the grant date.